A novel blood test could greatly improve triage of victims of radiation accidents by rapidly predicting who will survive, who will die, and who should receive immediate medical countermeasures, according to scientists at Dana-Farber Cancer Institute. In pre-clinical trials, the test was able to reveal within 24 hours whether survivable doses of radiation or doses that caused severe injury to the bone marrow and other organs would eventually prove fatal. Use of such a test, the researchers state, could facilitate timely medical intervention and improve overall survival of exposed individuals.
The team state that unlike current methods, their blood biomarker test quickly determines the functional impact of radiation rather than the dose to which the individual was exposed. Often, the effects of severe radiation exposure develop slowly over weeks or months. Current methods, such as observing when radiation sickness appears, are inexact and don’t measure the extent of long-term injury to the bone marrow and other organs.
Previous studies have shown that after a radiation release, there is currently no way to tell who was exposed and who wasn’t, and if someone was exposed, if it is lethal or not. Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms. The need for faster, more definitive predictive tests was highlighted by radiation accidents such as the 2011 reactor meltdown at the Fukushima Daiichi plant in Japan, radiation releases from Chernobyl and Three Mile Island, as well as the potential for terrorist radiologic weapons. The team undertook the current study with federal funds designated for radiation exposure biomarkers research in the wake of the Fukushima accident.
In a search for such biomarkers, the current study focused on microRNAs, or miRNAs. These are tiny RNA molecules, first identified about 20 years ago, that help regulate gene activity. They are made in cells, but some miRNAs are found in the bloodstream, and the scientists asked whether varying doses of radiation might cause corresponding changes in miRNA in the blood.
The data findings showed that 68 of 170 miRNAs detected in blood serum changed with radiation exposure, and these were narrowed down to a small number that acted as a signature of radiation dose. Mice exposed to two radiation doses, one lethal and one survivable, showed no outward differences for three to four weeks. But using the miRNA signature, the scientists were able to predict within 24 hours which animals would survive.
The team explain that an indication that the test would work similarly in people came from experiments using mice who received transplants of human bone marrow. The blood test gave the same indication of damage to the human cells as it had in the previous experiments with non-humanized mice. In addition, when the researchers gave the mice a radiation protection drug that rescued many of the human cells, the miRNA test results confirmed this protective effect.
The researchers noted that the miRNA changes that can be seen at 24 hours after the exposure disappear in a matter of days, so they plan to look for other miRNA signatures that have a longer duration.
Source: Dana-Farber Cancer Institute
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.